The CANTOS study (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) enrolled 10 061 patients with a history of recent myocardial infarction and elevated hsCRP levels, randomly assigning them to receive either placebo or different doses of subcutaneous canakinumab, an IL-1β-targeting monoclonal antibody.116 Canakinumab significantly reduced IL-6 and hsCRP levels in a dose-dependent manner, with the higher doses (150 and 300 mg) decreasing the primary end point of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death by 15% compared with placebo. This evidence concerns the gene IL1B and myocardial infarction.